The neutrophil-to-lymphocyte ratio (NLR) is a biomarker that is increased in patients with active gout. touchIMMUNOLOGY were delighted to speak with Prof. Michael Pillinger (NYU Grossman School of Medicine, New York, NY, USA) to discuss the pathophysiology of gout flares and the rationale for the NLR as a biomarker for systemic inflammation in gout.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials.’ (Abstract number: 1803) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- Could you give us a brief overview of the pathophysiology of gout flares? (0:16)
- What is the rationale for the use of the neutrophil-to-lymphocyte ratio (NLR) as a biomarker for systemic inflammation in gout? (3:01)
Disclosures: Michael Pillinger discloses consulting for Fortress Biotech and Horizon Therapeutics and receiving grant/ research support from Hikma Pharmaceuticals and Horizon Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
